This opportunity funds preclinical and patient-based research to understand how incretin mimetics, including GLP-1 and GIP-1 agents, affect cancer risk. The focus is on mechanisms driving increased or decreased risk of obesity-related cancers, excluding clinical trials. It aims to attract scientists investigating dynamic biological changes caused by these agents.
Eligible applicants include a wide range of U.S. organizations such as state and local governments, tribal organizations, small businesses, nonprofits, and institutions of higher education. Specific eligibility details should be confirmed with the funding organization.
